SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Nucl Med. 2008; 49 (Supplement 1):335P
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Aarts, F.
Right arrow Articles by Goldenberg, D.
PubMed
Right arrow Articles by Aarts, F.
Right arrow Articles by Goldenberg, D.

Oncology-Basic Science: Therapy, Metrics & Intervention

Therapy, Metrics & Intervention Posters

Radioimmunoscintigraphy of colorectal cancer using a two-step pre-targeting method

Frits Aarts1, Otto Boerman2, Robert Sharkey4, Thijs Hendriks2, Chien-Hsing Chang3, William McBride3, Rob Bleichrodt2, Wim Oyen1 and David Goldenberg4

1 Nuclear Medicine; ; 2 Surgery, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; ; 3 Immunomedics, Morris Plains, New Jersey; ; 4 Gardens State Cancer Center, Belleville, New Jersey

1420

Objectives: To explore the potential of pretargeted tumor imaging in colorectal cancer, using bispecific antibodies (bsAb) and an In-111-labeled peptide.

Methods: Pretargeted imaging with an anti-CEA x anti-DTPA bsAb and an In-111-labeled peptide was performed in patients with primairy colorectal cancer. In three patients the pharmacokinetics and tumor targeting of the peptide alone was studied. Nine patients received 5 mg bsAb and 3, 4 or 5 days later 5 mCi In-111-labeled peptide was injected to assess the optimal interval between bsAb and peptide injection. Images were acquired 1, 4 and 24 h p.i. of the peptide.

Results: In one patient, pre-operative PET imaging showed inguinal and para-aortic lymph node involvement. Adverse events (localized erythema) were seen in two patients. Peptide pharmacokinetics showed enhanced blood levels of the peptide in patients in the 3-day interval cohort as compared to the other cohorts. The peptide alone did not accumulate in the tumor. The best images were acquired with a 3- and 4-day interval, at 24 h after injection of the radiolabeled peptide. Imaging sensitivity was 78%. The PET positive lymph nodes were clearly visualized. Tumor to background ratios were 4.5:1-6.5-1 in the 3-day interval group, 6.0:1-16.6:1 in the 4-day interval group and 3.9:1-8.3:1 in the 5-day interval group.

Conclusions: Imaging of colorectal cancer using this pretargeting system showed best imaging results 24 hours after peptide administration with a 3- or 4-day interval.





Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Aarts, F.
Right arrow Articles by Goldenberg, D.
PubMed
Right arrow Articles by Aarts, F.
Right arrow Articles by Goldenberg, D.